Health Care [ 6/12 ] | Biotechnology [ 27/74 ]
NASDAQ | Common Stock
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.
RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -1.22 Decreased by -52.50% | -0.36 Decreased by -243.57% |
| Nov 11, 24 | -0.47 Increased by +42.22% | -0.56 Increased by +15.39% |
| Aug 8, 24 | -0.71 Decreased by -7.58% | -0.72 Increased by +1.39% |
| May 9, 24 | -0.79 Decreased by -3.95% | -0.81 Increased by +2.47% |
| Mar 7, 24 | -0.80 Decreased by -25.00% | -0.86 Increased by +6.98% |
| Nov 13, 23 | -0.82 Decreased by -30.16% | -0.75 Decreased by -9.33% |
| Aug 11, 23 | -0.66 Decreased by -6.45% | -0.78 Increased by +15.38% |
| May 11, 23 | -0.76 Decreased by -10.14% | -0.68 Decreased by -11.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -53.25 M Decreased by -72.46% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -18.43 M Increased by +41.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -27.66 M Decreased by -9.43% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -30.52 M Decreased by -13.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 5.29 M Increased by +724.96% | -30.88 M Decreased by -43.80% | Decreased by -583.89% Increased by +82.57% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -31.37 M Decreased by -50.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -25.28 M Decreased by -29.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -26.98 M Decreased by -33.84% | Decreased by N/A% Decreased by N/A% |